Gender differences in clinical outcome after coronary artery stenting with use of glycoprotein IIb/IIIa inhibitors

被引：20

作者：

Iakovou, L ^{[1
]}

Dangas, G ^{[1
]}

Mehran, R ^{[1
]}

Lansky, AJ ^{[1
]}

Kobayashi, Y ^{[1
]}

Adamian, M ^{[1
]}

Polena, S ^{[1
]}

Collins, MB ^{[1
]}

Roubin, GS ^{[1
]}

Stone, GW ^{[1
]}

Leon, MB ^{[1
]}

Moses, JW ^{[1
]}

机构：

[1] Cardiovasc Res Fdn, Lenox Hill Heart & Vasc Inst, New York, NY 10022 USA

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2002年 / 89卷 / 08期

关键词：

D O I：

10.1016/S0002-9149(02)02251-8

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We identified 1,215 patients (322 women, 26.5%) who received glycoprotein (GP) IIb/IIIa inhibitors during 1,852 coronary artery stenting procedures. Compared with men, women had similar rates of in-hospital ischemic events and vascular complications, and similar 1-month major adverse cardiac events rates. Therefore. use of the GP Ilb/IIIa inhibitors appears to eliminate the previously noted "disadvantages" in women with respect to early clinical outcome after interventional procedures.

引用

页码：976 / +

页数：5

共 20 条

[1]

BARRETTCONOR E, 1991, JAMA-J AM MED ASSOC, V265, P621

[2] USE OF A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY [J].

CALIFF, RM ;

SHADOFF, N ;

VALETT, N ;

BATES, E ;

GALEANA, A ;

KNOPF, W ;

SHAFTEL, J ;

BENDER, MJ ;

AVERSANO, T ;

RAQUENO, J ;

GURBEL, P ;

COWFER, J ;

COHEN, M ;

CROSS, P ;

BITTL, J ;

EDDINGS, K ;

TAYLOR, M ;

DEROSA, K ;

HATTEL, L ;

COOPER, L ;

ESHELMAN, B ;

FINTEL, D ;

NIEMYSKI, P ;

KLEIN, L ;

KENNEDY, H ;

THORNTON, T ;

KEREIAKES, D ;

MARTIN, L ;

ANDERSON, L ;

HIGBY, N ;

ELLIS, S ;

BREZINA, K ;

GEORGE, B ;

CHAPEKIS, A ;

SMITH, D ;

ANWAR, A ;

GERBER, TL ;

PRITCHARD, GL ;

MYLER, R ;

SHAW, R ;

MURPHY, M ;

WARD, K ;

MADIGAN, NP ;

BLANKENSHIP, J ;

HALBERT, M ;

FLANAGAN, C ;

TANNENBAUM, M ;

POLICH, M ;

STEVENSON, C ;

TCHENG, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (14) :956-961

[3] THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI) TRIAL, PHASE-I - A COMPARISON BETWEEN INTRAVENOUS TISSUE PLASMINOGEN-ACTIVATOR AND INTRAVENOUS STREPTOKINASE - CLINICAL FINDINGS THROUGH HOSPITAL DISCHARGE [J].

CHESEBRO, JH ;

KNATTERUD, G ;

ROBERTS, R ;

BORER, J ;

COHEN, LS ;

DALEN, J ;

DODGE, HT ;

FRANCIS, CK ;

HILLIS, D ;

LUDBROOK, P ;

MARKIS, JE ;

MUELLER, H ;

PASSAMANI, ER ;

POWERS, ER ;

RAO, AK ;

ROBERTSON, T ;

ROSS, A ;

RYAN, TJ ;

SOBEL, BE ;

WILLERSON, J ;

WILLIAMS, DO ;

ZARET, BL ;

BRAUNWALD, E .

CIRCULATION, 1987, 76 (01) :142-154

[4] Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender - Pooled analysis from EPIC, EPILOG and EPISTENT trials [J].

Cho, L ;

Topol, EJ ;

Balog, C ;

Foody, JM ;

Booth, JE ;

Cabot, C ;

Kleiman, NS ;

Tcheng, JE ;

Califf, R ;

Lincoff, MA .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (02) :381-386

[5] Hospital mortality in women and men with acute cardiac ischemia: A prospective multicenter study [J].

Coronado, BE ;

Griffith, JL ;

Beshansky, JR ;

Selker, HP .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 29 (07) :1490-1496

[6] Platelet glycoprotein IIb IIIa antagonists in percutaneous coronary revascularization [J].

Dangas, G ;

Colombo, A .

AMERICAN HEART JOURNAL, 1999, 138 (01) :S16-S23

[7]

*EPILOG INV, 1997, NEW ENGL J MED, V350, P1689

[8]

Hanrath P, 1997, CIRCULATION, V96, P1445

[9] MECHANISMS OF DISEASE - PLATELET GLYCOPROTEIN IIB/IIIA RECEPTORS IN CARDIOVASCULAR MEDICINE [J].

LEFKOVITS, J ;

PLOW, EF ;

TOPOL, EJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (23) :1553-1559

[10] Atherosclerotic plaque burden and CK-MB enzyme elevation after coronary interventions - Intravascular ultrasound study of 2256 patients [J].

Mehran, R ;

Dangas, G ;

Mintz, GS ;

Lansky, AJ ;

Pichard, AD ;

Satler, LF ;

Kent, KM ;

Stone, GW ;

Leon, MB .

CIRCULATION, 2000, 101 (06) :604-610

← 1 2 →